ResearcherInstitució Catalana de Recerca i Estudis AvançatsActive in the last 2 years
Laura Soucek
Matched on ORCID iD 0000-0002-4750-7971; OpenAlex author ID A5058419452. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 25
2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper
Papers 5
- A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway Co-author DOI 10.64898/2025.12.12.693851↗
- MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype. Co-author DOI 10.1158/2159-8290.cd-19-0435↗
- BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC. Last author DOI 10.18632/oncotarget.24648↗
- Pancreatic cancer heterogeneity and response to Mek inhibition. Co-author DOI 10.1038/onc.2017.174↗
- Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. Last author DOI 10.1158/0008-5472.can-14-2852↗
Closest collaborators
The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Daniel Massó-Vallés · 3 shared papers, 2015–2018 · strength 0.18
- Paper BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC. DOI 10.18632/oncotarget.24648↗
- Paper Pancreatic cancer heterogeneity and response to Mek inhibition. DOI 10.1038/onc.2017.174↗
- Paper Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. DOI 10.1158/0008-5472.can-14-2852↗
- Lisa M. Coussens · 1 shared paper, 2025 · strength 0.15
- Gordon Brent Mills · 1 shared paper, 2025 · strength 0.15
- Vidhi M. Shah · 1 shared paper, 2025 · strength 0.15
- Patrick Joseph Worth · 1 shared paper, 2025 · strength 0.15
- Isabel A. English · 1 shared paper, 2025 · strength 0.15
- Adel Kardosh · 1 shared paper, 2025 · strength 0.15
- Katie E. Blise · 1 shared paper, 2025 · strength 0.15
- Jason M. Link · 1 shared paper, 2025 · strength 0.15
- Motoyuki Tsuda · 1 shared paper, 2025 · strength 0.15
- Ethan S. Agritelley · 1 shared paper, 2025 · strength 0.15
- Rosalie C. Sears · 1 shared paper, 2025 · strength 0.15
- Jonathan Robert Brody · 1 shared paper, 2025 · strength 0.15
- Charles D. Lopez · 1 shared paper, 2025 · strength 0.15
- Nicole M. Sodir · 2 shared papers, 2015–2020 · strength 0.15
- Gérard I. Evan · 2 shared papers, 2015–2020 · strength 0.15
- Toni Jauset · 2 shared papers, 2015–2018 · strength 0.12
- Kim Pedersen · 2 shared papers, 2015–2017 · strength 0.10
- Joaquı́n Arribas · 2 shared papers, 2015–2017 · strength 0.10
- Faiz Bilal · 1 shared paper, 2017 · strength 0.06
- Irit Sagi · 1 shared paper, 2017 · strength 0.06
- Vishnu Mohan · 1 shared paper, 2017 · strength 0.06
- Josep M. Tabernero · 1 shared paper, 2017 · strength 0.06
- Ana P. Vivancos · 1 shared paper, 2017 · strength 0.06
- Teresa Mercade Macarulla · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.